No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

FX Solutions, SAS. [FX Shoulder, Inc.] Completes Easytech Reversed® Stemless IDE Enrollment in the USA

The First-and-Only Completed Stemless Reverse IDE in the USA

Editor: What To Know

  •   As a small company, we are excited and humbled to lead the way and be the first to complete this historic study that may bring a novel device to the U.
  • The Easytech Reversed® Stemless features peripheral fixation of the humeral component that is designed to be more bone sparing as compared to the traditional stemmed devices and its unique-to-market design for improved fixation to withstand the forces of reverse total shoulder arthroplasty.
  • “It has been a real pleasure over the last couple of years to participate in this IDE to offer patients a novel solution and to see very favorable outcomes for my patients.

FX has completed the enrollment for their Investigational Device Exemption [IDE] study [G180100] on the Easytech Reversed® Stemless for reverse total shoulder arthroplasty becoming the first-and-only to do so.

“This is not only a major milestone for FX, but for the next generation of stemless shoulder arthroplasty and the way we think about reverse total shoulder arthroplasty.  As a small company, we are excited and humbled to lead the way and be the first to complete this historic study that may bring a novel device to the U.S. market which has already seen over 2000 implanted in Europe since 2015,” said Baptiste Martin, CEO of FX Shoulder USA.

The study, that began in December of 2018 and concluded enrollment, consisted of (90) subjects completed across (7) sites.

“It has been a real pleasure over the last couple of years to participate in this IDE to offer patients a novel solution and to see very favorable outcomes for my patients.  Stemless shoulder replacement is here to stay, and it was great being part of the trailblazing group to bring it to the U.S.,” said Michael Bradley, MD, MBA, MS of Ortho Rhode Island in Wakefield, RI.

The Easytech Reversed® Stemless features peripheral fixation of the humeral component that is designed to be more bone sparing as compared to the traditional stemmed devices and its unique-to-market design for improved fixation to withstand the forces of reverse total shoulder arthroplasty.

The Easytech Reversed® anchor base is designed to fit peripherally just inside the cortical bone with optimal bone quality for fixation.  It is the first-and-only stemless on the market with peripheral fixation which has been in use in the European market since 2015.

“The Easytech Reversed® is a unique stemless solution for reverse TSA to provide patients with an anatomically centered humeral articulating component that is bone sparing and has excellent fixation,” said Howard W. Harris, MD of Southlake, TX.

FX Shoulder USA, Inc. is based in Dallas, TX and is the direct provider of FX Solutions shoulder replacement devices in the U.S.  FX Shoulder USA, Inc., founded in January 2018, focuses exclusively on shoulder arthroplasty.  For additional information, please visit www.fxshoulder.com.

CAUTION: Investigational Device.  Limited by Federal (or United States) Law to investigational use. (21 CFR812.5(a)) FDA: NCT 03806842.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy